24 March 2014 - Around 900 cancer patients a year could now benefit from treatment with a trio of medicines just added to England's Cancer Drugs Fund, a cash pot of £200 million a year designed to offer access to medicines not routinely funded by the NHS.

Patients will have the chance to access albumin bound paclitaxel (Celgene's Abraxane), bevacizumab (Roche's Avastin) and cabozantinib (Exelixis' Cometriq) on the NHS if their doctor believes them to be the most appropriate treatment.

For more details, go to: http://www.pharmatimes.com/Article/14-03-24/Three_more_drugs_make_England_s_Cancer_Drugs_Fund.aspx?#ixzz2wuquniiF